

Supplementary material

Babicki M, Kołat D, Kapusta J, et al. Prevalence and assessment of risk factors among Polish adults with post-COVID-19 syndrome: a 12-month follow-up study. *Pol Arch Intern Med.* 2023; 133: 16512. doi:10.20452/pamw.16512

Please note that the journal is not responsible for the scientific accuracy or functionality of any supplementary material submitted by the authors. Any queries (except missing content) should be directed to the corresponding author of the article.

Table S1. A detailed list of clinical symptoms in the 3rd and 12th month after the onset of COVID-19.

Symptoms		Number of patients		p
		3 months N (%)	12 months N (%)	
Asthenia	Fatigue	445 (69.2)	220 (34.2)	<0.001
	Worse tolerance of exercise	399 (62.1)	230 (35.7)	<0.001
Sensory	Taste and olfactory dysfunction	84 (13.1)	48 (7.5)	<0.001
Dermatological	Hair loss	179 (27.8)	123 (19.1)	<0.001
	Skin lesions	49 (7.6)	28 (4.4)	<0.001
	Excessive sweating	193 (30.0)	103 (16.0)	<0.001
Neurocognitive	Headache	187 (29.1)	102 (15.9)	<0.001
	Memory and concentration problems	288 (44.8)	234 (36.4)	<0.001
	Other neurological symptoms	17 (2.6)	3 (0.5)	0.004
Musculoskeletal	Arthralgia	7 (1.1)	6 (0.9)	0.01
	Myalgia	160 (24.8)	108 (16.8)	<0.001
Cardiovascular	Palpitations	317 (49.3)	150 (23.3)	<0.001
	Stenocardial symptoms	2 (0.3)	0 (0.0)	<0.001
	Peripheral edema	93 (14.5)	49 (7.6)	<0.001
	Venous thromboembolism	10 (1.5)	7 (1.1)	<0.001
	Newly diagnosed arterial hypertension	112 (17.4)	76 (11.8)	<0.001
	Fainting/unconsciousness	21 (3.3)	9 (1.4)	<0.001
Respiratory	Dyspnoea	199 (30.9)	89 (13.9)	<0.001
	Cough	148 (23.0)	73 (11.4)	<0.001
	Chest pain	237 (36.8)	87 (13.5)	<0.001